본문 바로가기
KERD
논문KCI 등재

위장관기질종양의 진단과 치료

Diagnosis and Treatment of Gastrointestinal Stromal Tumor

구동회|강윤구
대한내과학회 (The Korean Association Of Internal Medicine)|2013.10|대한내과학회지 (The Korean Journal of Medicine)|제85권 제4호|pp. 341-353|DOI http://dx.doi.org/10.3904/kjm.2013.85.4.341

0

조회

0

다운로드

4

인용

0

참고문헌

키워드

Treatment진단치료DiagnosisImatinibRegorafenibSunitinib위장관기질종양이마티닙수니티닙레고라페닙GIST
주제분류내과학

초록

본 종설은 최신 연구결과들을 수집하여 국내 위장관기질종양 환자들을 진료하는 임상에 실질적인 도움이 되도록 작성되었다. 그 동안 위장관기질종양의 진단 및 수술과 약물 치료에 대해 연구를 지속하면서 국외의 새로운 연구 결과들뿐 아니라 우리나라 환자들을 대상으로 시행된 연구들을 검토하고 적절한 진료지침을 만들기 위해 물심양면으로 애써주신 대한위장관기질종양연구회 회원들과 임원진 여러분께 감사를 드린다. 본 종설을 통하여 위장관기질종양의 진단의 확실성을 높이고, 임상 현장에서 환자들의 진료 및 치료에 도움이 되기를 기대한다.

Abstract

Gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, have represented an important advance in oncology field with the success of molecular targeted therapy. Since the approval of the tyrosine kinase inhibitor (imatinib) in 2002, the survival of patients with advanced GISTs has significantly increased. Accurate histopathologic diagnosis of GISTs and multidisciplinary approach has become more important for successful management of GISTs. Recently, imatinib has become a standard treatment even in adjuvant setting, and regorafenib has been approved for advanced GIST after failure of imatinib and sunitinib. This review presents here the updated results of relevant clinical studies for the further revision to the guideline of Korean GIST study group. We hope this review will help enhance the quality of diagnosis, treatment, and care of patients with GIST in Korea.

참고문헌 (66)

  1. 강윤구, "Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea", Cancer Research and Treatment, 44(2), pp.85~96 (2012), 대한암학회[DOI]
  2. Corless CL, "Biology of gastrointestinal stromal tumors", J Clin Oncol, 22, pp.3813~3825 (2004)
  3. Hirota S, "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors", Science, 279, pp.577~580 (1998)
  4. Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
  5. Yarden Y, "Human protooncogene c-kit : a new cell surface receptor tyrosine kinase for an unidentified ligand", EMBO J, 6, pp.3341~3351 (1987)
  6. Miettinen M, "Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis", Virchows Arch, 438, pp.1~12 (2001)
  7. Zöller ME, "Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population", Cancer, 79, pp.2125~2131 (1997)
  8. Carney JA, "The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma", N Engl J Med, 296, pp.1517~1518 (1977)
  9. Janeway KA, "Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations", Proc Natl Acad Sci U S A, 108, pp.314~318 (2011)
  10. Carney JA, "Familial paraganglioma and gastric stromal sarcoma : a new syndrome distinct from the Carney triad", Am J Med Genet, 108, pp.132~139 (2002)
  11. Fletcher CD, "Diagnosis of gastrointestinal stromal tumors : a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
  12. Liegl B, "Contemporary pathology of gastrointestinal stromal tumors", Hematol Oncol Clin North Am, 23, pp.49~68 (2009)
  13. Kim KM, "PKCtheta expression in gastrointestinal stromal tumor", Mod Pathol, 19, pp.1480~1486 (2006)
  14. Lee HE, "Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining", J Clin Pathol, 61, pp.722~729 (2008)
  15. Medeiros F, "KIT-negative gastrointestinal stromal tumors : proof of concept and therapeutic implications", Am J Surg Pathol, 28, pp.889~894 (2004)
  16. Orosz Z, "Gastrointestinal stromal tumors : a clinicopathologic and immunohistochemical study of 136 cases", Pathol Oncol Res, 11, pp.11~21 (2005)
  17. Kang GH, "DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors", Mod Pathol, 24, pp.866~875 (2011)
  18. Ryu MH, "Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate", Jpn J Clin Oncol, 36, pp.17~24 (2006)
  19. Miettinen M, "Gastrointestinal stromal tumors : pathology and prognosis at different sites", Semin Diagn Pathol, 23, pp.70~83 (2006)
  20. Joensuu H., "Risk stratification of patients diagnosed with gastrointestinal stromal tumor", Hum Pathol, 39, pp.1411~1419 (2008)
  21. Fletcher CD, "Int J Surg Pathol", Int J Surg Pathol, 10, pp.81~89 (2002)
  22. Miettinen M, "Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis", Arch Pathol Lab Med, 130, pp.1466~1478 (2006)
  23. Hornick JL, "The role of KIT in the management of patients with gastrointestinal stromal tumors", Hum Pathol, 38, pp.679~687 (2007)
  24. Miettinen M, "Gastrointestinal stromal tumors : recent advances in understanding of their biology", Hum Pathol, 30, pp.1213~1220 (1999)
  25. Blay JY, "Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO", Ann Oncol, 16, pp.566~578 (2005)
  26. Gold JS, "Combined surgical and molecular therapy : the gastrointestinal stromal tumor model", Ann Surg, 244, pp.176~184 (2006)
  27. Iwahashi M, "Surgical management of small gastrointestinal stromal tumors of the stomach", World J Surg, 30, pp.28~35 (2006)
  28. 공성호, "Surgical Treatment of Gastric Gastrointestinal Stromal Tumor", 대한위암학회지, 13(1), pp.3~18 (2013), 대한위암학회
  29. Choi SM, "Laparoscopic wedge resection for gastric GIST : long-term follow-up results", Eur J Surg Oncol, 33, pp.444~447 (2007)
  30. Novitsky YW, "Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors", Ann Surg, 243, pp.738~745 (2006)
  31. Otani Y, "Operative indications for relatively small(2-5 cm)gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases", Surgery, 139, pp.484~492 (2006)
  32. DeMatteo RP, "Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival", Ann Surg, 231, pp.51~58 (2000)
  33. Raut CP, "Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors", J Clin Oncol, 24, pp.2325~2331 (2006)
  34. Sym SJ, "Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors(GISTs)", J Surg Oncol, 98, pp.27~33 (2008)
  35. Park SJ, "The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST", J Clin Oncol 2013 Gastrointestinal Cancers Symposium, 31(4) (2013)
  36. Hislop J, "for the treatment of people with unresectable", metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose, 2012, pp.43, 168~176
  37. Dematteo RP, "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebo-controlled trial", Lancet, 373, pp.1097~1104 (2009)
  38. Joensuu H, "One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trial", JAMA, 307, pp.1265~1272 (2012)
  39. Bümming P, "Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients", Br J Cancer, 89, pp.460~464 (2003)
  40. Loughrey MB, "Gastrointestinal stromal tumour treated with neoadjuvant imatinib", J Clin Pathol, 58, pp.779~781 (2005)
  41. 오지선, "Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases", Cancer Research and Treatment, 38(3), pp.179~183 (2006), 대한암학회
  42. Liegl B, "Contemporary pathology of gastrointestinal stromal tumors", Hematol Oncol Clin North Am, 23, pp.49~68 (2009)
  43. An HJ, "The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST", J Clin Oncol, 30 (2012)
  44. Dematteo RP, "Clinical management of gastrointestinal stromal tumors : before and after STI-571", Hum Pathol, 33, pp.466~477 (2002)
  45. Verweij J, "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial", Lancet, 364, pp.1127~1134 (2004)
  46. Debiec-Rychter M, "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours", Eur J Cancer, 42, pp.1093~1103 (2006)
  47. "NCCN clinical practice guidelines in oncology: soft tissue sarcoma: version 3" (2012)[URL]
  48. Kim TW, "Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors", Oncologist, 14, pp.540~547 (2009)
  49. Du CY, "The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor(GIST)", J Surg Oncol, 98, pp.175~178 (2008)
  50. Yeh CN, "Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST : preliminary experience from Chang Gung Memorial Hospital", Ann Surg Oncol, 14, pp.1123~1128 (2007)
  51. Kang HJ, "Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors(GIST) : the Korean GIST Study Group(KGSG)Study", Acta Oncol, 51, pp.528~536 (2012)
  52. "Imatinib dose escalation to 800 mg/day in Korean patients with metastatic or unresectable GIST harboring KIT exon 9 mutation (NCT01541709)"[URL]
  53. Patrikidou A, "Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial", Ann Oncol, 24, pp.1087~1093 (2013)
  54. Antoch G, "Comparison of PET, CT, and dual-modality PET", CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors, 2004, pp.45, 357~365
  55. Jager PL, "Imatinib mesylate for the treatment of gastrointestinal stromal tumours : best monitored with FDG PET", Nucl Med Commun, 25, pp.433~438 (2004)
  56. Stroobants S, "18FDGPositron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate(Glivec)", Eur J Cancer, 39, pp.2012~2020 (2003)
  57. Choi H, "CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment : a quantitative analysis correlated with FDG PET findings", AJR Am J Roentgenol, 183, pp.1619~1628 (2004)
  58. Choi H, "Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate : proposal of new computed tomography response criteria", J Clin Oncol, 25, pp.1753~1759 (2007)
  59. Linton KM, "Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases", Br J Radiol, 79, pp.40~44 (2006)
  60. Desai J, "Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors", Clin Cancer Res, 13(18), pp.5398~5405 (2007)
  61. Bauer S, "Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib", Int J Cancer, 117, pp.316~325 (2005)
  62. Zalcberg JR, "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg", Eur J Cancer, 41, pp.1751~1757 (2005)
  63. Park I, "Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor", Jpn J Clin Oncol, 39, pp.105~110 (2009)
  64. Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)
  65. Demetri GD, "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.295~302 (2013)
  66. Kang Y-K, "Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and", or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study, 2013, ~

관련 논문AI추천

Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea강윤구, 강혜진, 김경미, 김우호, 류민희, 손태성, 양한광, 최동일대한암학회 · Cancer Research and Treatment2012 · 제44권 제2호Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor강윤구, 구동회, 김경미, 류민희, 양한광, Akira Sawaki, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Jie Zheng, Lin Shen, Li-Tzong Chen, Seiichi Hirota, Toshirou Nishida대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호줄기를 형성한 위의 관외형 위장관간질종양 1예구자설, 김영진, 김은선, 류호상, 박낙순, 이동훈, 이상우, 이홍식, 임현준, 정성우, 최재현대한소화기내시경학회 · Clinical Endoscopy2007 · 제35권 제5호위 밖으로 성장한 위장관 간질종양 1예박혁, 김도현, 김수현, 김호동, 이상률, 이영직, 전원정대한내과학회 · 대한내과학회지2006 · 제71권 제6호위와 소장에서 발생한 위장관기질종양의 예후 비교분석 - 단일기관 126예를 대상으로 한 후향적 연구 -김상운, 김세원, 김준모, 배영경, 배정민, 석상희, 송선교대한병리학회 · Journal of Pathology and Translational Medicine2008 · 제42권 제6호조기 위암에서 전이성 림프절과 감별이 필요하였던 관외형 위장관 기질종양 1예김종원, 김지현, 박정수, 박형순, 박효진, 윤선옥, 윤영훈, 조은나대한소화기내시경학회 · Clinical Endoscopy2010 · 제41권 제5호

이 간행물의 다른 논문 (6건)

신경내분비종양박영석pp. 354-356진행성 악성 흑색종(Malignant Melanoma)의 새로운 내과적 치료이수정, 채의수pp. 357-363골다공증 치료의 최신 지견: 누구를, 무엇으로, 얼마 동안 치료할 것인가?김상완pp. 364-373재발성 췌장암으로 항암화학요법을 시행한 환자에서 발생한 복부 방선균증조인래, 한민석, 이승우, 조중현, 박정엽, 조동후, 송시영pp. 401-405건강한 성인에서 마라톤 경기 중 발생한 급성 심근경색증 2예홍경순, 윤덕형, 민현준, 안평, 이병무, 최현희, 박상현pp. 411-415
원문 보기